null

SMILES: Cc1cc(cc2[nH]c3c(ccc(-c4cccc(c4C)-n4c(=O)n(C)c5c(F)cccc5c4=O)c3c12)C(N)=O)C(C)(C)O

InChI Key: InChIKey=BEVUBRZINAWGDH-UHFFFAOYSA-N

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 2 hits for monomerid = 264152   

Target/Host (Institution)	Ligand	Target/Host Links	Ligand Links	Trg + Lig Links	Ki nM	ΔG° kcal/mole	IC50 nM	Kd nM	EC50/IC50 nM	koff s-1	kon M-1s-1	pH	Temp °C
Tyrosine-protein kinase JAK2 (Homo sapiens (Human))	BDBM264152 (4-(3-(S)-(8-Fluoro-1-methyl(d3)-2,4-dioxo-1,2-dihy...) Show SMILES Cc1cc(cc2[nH]c3c(ccc(-c4cccc(c4C)-n4c(=O)n(C)c5c(F)cccc5c4=O)c3c12)C(N)=O)C(C)(C)O |(-3.01,-.34,;-3.01,1.2,;-4.54,1.04,;-5.44,2.28,;-4.82,3.69,;-3.29,3.85,;-2.38,5.1,;-.92,4.62,;.42,5.39,;1.75,4.62,;1.75,3.08,;.42,2.31,;.42,.77,;-.92,,;-.92,-1.54,;.42,-2.31,;1.75,-1.54,;1.75,,;3.08,.77,;3.08,-2.31,;3.08,-3.85,;1.75,-4.62,;4.42,-4.62,;4.42,-6.16,;5.75,-3.85,;7.09,-4.62,;7.09,-6.16,;8.42,-3.85,;8.42,-2.31,;7.09,-1.54,;5.75,-2.31,;4.42,-1.54,;4.42,,;-.92,3.08,;-2.38,2.6,;.42,6.93,;1.75,7.7,;-.92,7.7,;-6.93,1.88,;-7.33,.4,;-8.42,1.48,;-8.02,2.97,)| Show InChI InChI=1S/C33H29FN4O4/c1-16-14-18(33(3,4)42)15-24-26(16)27-20(12-13-21(30(35)39)28(27)36-24)19-8-7-11-25(17(19)2)38-31(40)22-9-6-10-23(34)29(22)37(5)32(38)41/h6-15,36,42H,1-5H3,(H2,35,39)	PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	>2.00E+3	n/a	n/a	n/a	n/a	7.4	25
Bristol-Myers Squibb Company US Patent					Assay Description Compounds with activity against Jak2 tyrosine kinase have been observed to cause thrombocytopenia, anemia and neutropenia in human patients in clinic...				US Patent US9714234 (2017) BindingDB Entry DOI: 10.7270/Q2474CW0
					More data for this Ligand-Target Pair
Tyrosine-protein kinase BTK (Homo sapiens (Human))	BDBM264152 (4-(3-(S)-(8-Fluoro-1-methyl(d3)-2,4-dioxo-1,2-dihy...) Show SMILES Cc1cc(cc2[nH]c3c(ccc(-c4cccc(c4C)-n4c(=O)n(C)c5c(F)cccc5c4=O)c3c12)C(N)=O)C(C)(C)O |(-3.01,-.34,;-3.01,1.2,;-4.54,1.04,;-5.44,2.28,;-4.82,3.69,;-3.29,3.85,;-2.38,5.1,;-.92,4.62,;.42,5.39,;1.75,4.62,;1.75,3.08,;.42,2.31,;.42,.77,;-.92,,;-.92,-1.54,;.42,-2.31,;1.75,-1.54,;1.75,,;3.08,.77,;3.08,-2.31,;3.08,-3.85,;1.75,-4.62,;4.42,-4.62,;4.42,-6.16,;5.75,-3.85,;7.09,-4.62,;7.09,-6.16,;8.42,-3.85,;8.42,-2.31,;7.09,-1.54,;5.75,-2.31,;4.42,-1.54,;4.42,,;-.92,3.08,;-2.38,2.6,;.42,6.93,;1.75,7.7,;-.92,7.7,;-6.93,1.88,;-7.33,.4,;-8.42,1.48,;-8.02,2.97,)| Show InChI InChI=1S/C33H29FN4O4/c1-16-14-18(33(3,4)42)15-24-26(16)27-20(12-13-21(30(35)39)28(27)36-24)19-8-7-11-25(17(19)2)38-31(40)22-9-6-10-23(34)29(22)37(5)32(38)41/h6-15,36,42H,1-5H3,(H2,35,39)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	1.20	n/a	n/a	n/a	n/a	7.4	25
Bristol-Myers Squibb Company US Patent					Assay Description To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, INVITROGEN Corporation), fluoresceinated peptide (1.5 μM), A...				US Patent US9714234 (2017) BindingDB Entry DOI: 10.7270/Q2474CW0
					More data for this Ligand-Target Pair